Chapter 12: Nonsteroidal Antiasthma Agents

Chapter 12: Nonsteroidal Antiasthma Agents

Complete Chapter Questions With Answers

Sample Questions Are Posted Below

MULTIPLE CHOICE

1. The general indication for clinical use of nonsteroidal antiasthma agents is

ANS:  B

The general indication for clinical use of nonsteroidal antiasthma agents is prophylactic management, or control, of mild persistent asthma as put forth in the 2007 National Asthma Education and Prevention Program (NAEPP) Guidelines for the Diagnosis and Management of Asthma. These agents are not designed for short-term control or to reverse active bronchospasm.

REF:   p. 203

2. Nonsteroidal antiasthma drugs are

ANS:  D

All the drugs described in Chapter 12 are controllers, not relievers, and are used in asthma requiring antiinflammatory drug therapy.

REF:   p. 203

3. Accolate is the brand name for which medication?

ANS:  A

Accolate is the brand name for zafirlukast. Singulair is the brand name for montelukast, Zyflo is the brand name for zileuton, and Xolair is the brand name for omalizumab.

REF:   p. 204

4. Cromolyn sodium is available in what form?

ANS:  A

Cromolyn sodium is available only as a small volume nebulizer (SVN) formulation. The antileukotriene drugs zafirlukast, montelukast, and zileuton are available in tablet form.

REF:   p. 204

5. Which type of asthma is associated with allergic reactions?

ANS:  D

Extrinsic asthma is dependent on allergy, or atopy, whereas intrinsic asthma shows no evidence of sensitization to common inhaled allergens.

REF:   p. 203